GlassScriptPhysician profile
Melissa Thierry
NPI 1841541158
$5,036.25
in general payments reported to CMS, 2019-2025
24 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $594 · 2022: $768 · 2023: $1,453 · 2024: $905 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.55 |
| Education | $294.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,381.36 | 2021-2025 | |
| Janssen Biotech, INC. | $662.80 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $647.26 | 2021-2025 | |
| Galderma Laboratories, L.P. | $306.21 | 2022-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $282.32 | 2021-2025 | |
| Leo Pharma INC. | $244.10 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $217.20 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $168.53 | 2021-2025 | |
| Organon LLC | $165.70 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $155.01 | 2022-2025 | Sotyktu |
| Pfizer INC. | $144.39 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $110.97 | 2021-2023 | Dupixent |
| Amgen INC. | $101.69 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Incyte Corporation | $83.85 | 2022-2025 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $60.65 | 2024 | |
| Lilly USA, LLC | $40.42 | 2023-2024 | Ebglyss, Taltz, Olumiant |
| Revance Therapeutics, INC. | $38.75 | 2025 | Daxxify |
| Allergan, INC. | $28.06 | 2021 | |
| Fresenius Kabi USA, LLC | $22.73 | 2024 | Idacio |
| Hill Dermaceuticals, INC. | $22.67 | 2021 | |
| Almirall LLC | $19.28 | 2021 | |
| Kerecis Limited | $18.33 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Ucb, INC. | $14.97 | 2025 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Thierry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.